 SALT LAKE CITY--BUSINESS WIRE--PolarityTE, Inc. Nasdaq: PTE, a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding correspondence from the U.S. Food and Drug Administration FDA related to its Investigational New Drug Application IND for SkinTE with a proposed indication for chronic cutaneous ulcers, which was filed on July 23, 2021. The FDA provided feedback that certain Chemistry, Manufacturing, and Control CMC items nee 